Skip to main content

RotM: Interview with Prof. Steve Winder

For our recent Researcher of the Month, we spoke to Professor Steve Winder, Professor of Molecular Cell Biology, at the Department of Biomedical Science, The University of Sheffield. His laboratory focuses on the study of dystroglycan, a protein that plays an important role in cell adhesion and signalling. His recent paper in Human Molecular Genetics speaks about the a FDA approved drug, currently being used for treating leukemia as a treatment for Duchenne Muscular Dystrophy (DMD). Here is Professor Win
der telling us more about his lab's findings and how we might cure DMD in the near future. 

CTS : For the benefit of our readers, could you please tell us more about your  findings in the recent study. 
SW: Identification of a systemically acting and universal small molecule therapy for  Duchenne muscular dystrophy would be an enormous advance for this condition. Based on evidence gained from studies on mouse genetic models, we have identified tyrosine phosphorylation and degradation of β-dystroglycan as a key event in the aetiology of Duchenne muscular dystrophy. Thus, preventing tyrosine phosphorylation and degradation of β-dystroglycan presents itself as a potential therapeutic strategy. 

Using the dystrophic sapje zebrafish, we have investigated the use of tyrosine kinase and other inhibitors to treat the dystrophic symptoms in this model of Duchenne muscular dystrophy.
Dastanib or Sprycel may be used to cure Duchenne Muscular Dystrophy Image credit: Wikipedia
Molecular Structure of Dasatinib, a drug produced by Bristol-Myers Squibb and marketed as Sprycel
 
Dasatinib, a potent and specific Src tyrosine kinase inhibitor, was found to decrease the levels of β-dystroglycan phosphorylation on tyrosine and to increase the relative levels of non-phosphorylated β-dystroglycan in sapje zebrafish. Furthermore, dasatinib treatment resulted in the improved physical appearance of the sapje zebrafish musculature and increased swimming ability as measured by both duration and distance of swimming of dasatinib-treated fish compared with control animals. These data suggest great promise for pharmacological agents that prevent the phosphorylation of β-dystroglycan on tyrosine and subsequent steps in the degradation pathway as therapeutic targets for the treatment of Duchenne muscular dystrophy.

CTS: Of all Src inhibitors available, Why was dastanib chosen?
SW:We actually used the zebrafish system to screen many compounds and drugs. Dasatinib was just picked as an exemplar for publication. 

Image credit: doi: 10.1093/hmg/ddv469
Image showing significantly reduced movement in sapje fish in terms of distance covered when compared to their siblings A, results of movement tracking when compared, B, and improvement in movement when treated with dastanib, C. Image credit: Prof.Steve Winder and Human Molecular Genetics. 


CTS: Korner et al 2014 carried out a similar study with a compound called bortezomib. How different would you say is this study from theirs? 
SW: Korner et al used a mouse model of congenital muscular dystrophy(CMD) and treated it with a proteasome inhibitor, whereas we used a mouse model of DMD and a Src inhibitor. Interestingly the same group have recently shown that the same drug is not effective against a different mousemodel of the same disease.

CTS: So, would you be working on a different model of zebrafish to ensure that that your findings are reproducible?
SW: Given that we have already advanced our studies in mdx mice with some apparent success, there seems little need to go back to zebrafish at this stage.

CTS: Your lab has worked on mouse models earlier, why shift to zebrafish for this study?
SW: The mouse model demonstrated the importance of tyrosine phosphorylation in the aetiology of DMD. The shift to fish was simply for the purposes of screening many candidate compounds. Drug screening is much quicker, cheaper and easier in fish than in mice.

CTS:What happens next? Since this is an approved drug, can we skip the human trials altogether? 
SW:No, trials are still needed. Although dasatinib is approved clinically and the safety testing has been done, we will still need to demonstrate efficacy against DMD in people.

CTS: So, would your lab be involved in the clinical trials for Duchenne Muscular Dystrophy?
SW: The initial discovery is patented with us as inventors, however pharma involvement would be needed in order to obtain the drugs for the trial. The trial could be investigator led, or pharma could choose to do it. 

Prof. Steve Winder, University of Sheffield
Just a regular day at the office.
Image credit: Professor Steve Winder
CTS: Looking at the treatments in the future, isn't gene therapy a more robust answer to a genetic disease like DMD. When perfected, it holds promise of 100% recovery. Is your lab looking at gene replacement therapies as well?
SW: Whilst DMD is a monogenic disease, there are hundreds of different mutations. There is currently no single genetic therapy that is capable of correcting all the defects, and those that there are, are far from 100% perfect. Delivering these sorts of therapies to muscle remains problematic. CRISPR-Cas9 mediated gene editing would appear to be one way around that. 

However, we are not pursuing gene therapy approaches since that is not our current area of expertise.For the moment, a systemic small molecule inhibitor could be an answer. So although at present we are still working up the pharmacological approach, but ultimately a combinatorial regimen of pharmacological and genetic therapy may give greatest efficacy.

Readers interested to know about Duchenne Muscular Dystrophy would like to read our other post, Exception to the thumb rule.

If you would like to read more of these interesting stories from the world of science, subscribe to our  blog and we will send you an email every time we post something new and interesting. Alternatively, you can follow us on social media such as FacebookTwitter or Google Plus!

References:

Körner Z, Fontes-Oliveira CC, Holmberg J, Carmignac V, & Durbeej M (2014). Bortezomib partially improves laminin α2 chain-deficient muscular dystrophy. The American journal of pathology, 184 (5), 1518-28 PMID: 24631023

Körner Z, & Durbeej M (2016). Bortezomib Does Not Reduce Muscular Dystrophy in the dy2J/dy2J Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy. PloS one, 11 (1) PMID: 26731667

Lipscomb L, Piggott RW, Emmerson T, & Winder SJ (2016). Dasatinib as a treatment for Duchenne muscular dystrophy. Human molecular genetics, 25 (2), 266-74 PMID: 26604135

Comments

Popular posts from this blog

Do free energy magnetic motors really work?

The internet is rife with websites that promote generators that are capable of providing electricity without using any fuel. Built largely with magnets, these 'free energy generators' promise to cut your electricity bills and provide a much greener alternative to the electricity that is largely generated out of fossil fuels. Elaborate videos that give you estimates of how much money you can save without revealing any details of how to go about it, manage to keep the audience hooked on for a while, but $40 price tag, the loads of freebies and the instant $10 discount for not leaving the page, make the product and its seller highly suspicious. So, we decided to find out if these free energy magnetic motors really work?



The Principle

The magnetic motor works on the simple principle that we all already know, 'Like poles repel each other while opposite poles attract each other'. By arranging the magnets in a fashion where only like poles face each other, one can simply set t…

Why Sci-Hub’s story is so crucial to science?

On the 28th of October 2015, Judge Robert Sweet in his ruling at the New York district court declared that the website www.sci-hub.org be blocked with immediate effect and managed to stop hundreds and thousands of researchers and science enthusiasts from accessing the holy grail of today’s science, the research paper.
What should be a simple means to communicate to the world one’s research findings, has become a currency of some sort. A ticket to a researcher’s professional success, a magnet for an investigator to attract funding for his lab and the elusive piece of the puzzle that the publishing group can hold you ransom for, until you cough up some good cash ($30 or above for a single article and thousands of dollars for a bundled annual subscription)
What Judge Sweet termed as a “disservice (to) public interest”, is actually a small website that allows you access to scientific research, old and new, and for free. Sci- Hub. Org, started in 2011, as a trusted place to access research …

Generating electricity from flapping tree leaves

As kids, you might have spent many afternoons, under a huge tree, enjoying its shade. In a tropical country like India, trees are a welcome sight in the month of May, when the sun is blazing in the sky and the shade offered by them is a hundred thousand times better than artificial cooling of the air conditioning units. But never in our dream would we have thought that the rustling of the tiny leaves of the trees could one day make electricity for us.Because that requires a Hendersonian moment! (just in a bit)

This brilliant idea has come from the lab of a biophysicist at Iowa State University, Dr. Michael McCloskey, whose work at the University largely involves the study of membrane transport in algae and adult born neurons but also has a background in plant sciences. It was his colleague in the department of genetics, Dr. Eric Henderson who first came up with this plan of harvesting energy from leaves as he wondered how much kinetic energy was being generated when winds blow across l…

5 things driverless cars will do to change our future?

The race for building the world’s first commercially available driverless car is on. Google seems to be leading the pack and in its own charismatic style has been very open about it. Elon Musk’s Tesla is considered the second best with their cars having almost automated the driving process. Tech favourites, Apple also seem to be in the race but everything is under wraps, as of now, and there is not even a hint of what Apple is planning to make, the car, the software or simply make the car accessible with your Apple ID.
Once part of science fiction, driverless cars will soon be a part of our lives and with major automobile manufacturers such as General Motors, Toyota, Ford investing in the technology, prototypes of driverless cars will soon be seen on the roads. Before we get there, a quick review.
The Driverless car
The concept of automated driving has been around for close to a century but progress was slow due to unavailability of technology. For a car to be autonomous, it needs to kno…

Solar cells that work in rain

In case you have read my last month’s guest post about harvesting solar energy in rust, you would be delighted to know that there has been yet another breakthrough in our attempt to harness solar energy.  For many years, solar energy has been targeted for being unavailable at night and during rains. The problem of utilizing solar energy at night can be resolved with the help of metal oxide cells as elaborated in my above post (do read it, if you have not done so already). And now researchers at the Ocean University in China have addressed the second problem and developed solar cells that can actually use rain drops to generate electricity.
Published in the German journal Angewandte Chemie, the paper titled, A Solar Cell Triggered by Sun and Rain, opens a new realm of possibilities when harnessing solar energy. Coating the solar cell with a thin film of graphene allows the cell to function even when it is raining. Graphene is nothing but reduced form of graphite that consists of a hone…